July 12, 2019 - 4:17 PM EDT
Eton down 13% after hours on CRL for EM-100



Eton down 13% after hours on CRL for EM-100
  • Eton Pharmaceuticals (NASDAQ:ETON) announces that its partner [a subsidiary of Bausch Health Companies (NYSE:BHC) per a February 19 press release] received a Complete Response Letter (CRL) from the FDA regarding the partner's marketing application seeking approval for EM-100, an eye drop for the potential treatment of ocular itching associated with allergic conjunctivitis.
  • More news on: Eton Pharmaceuticals, Inc., Bausch Health Companies Inc., Healthcare stocks news, Stocks on the move,
  • Read more ...

Source: SeekingAlpha (July 12, 2019 - 4:17 PM EDT)